Drug Profile

IMP 10

Alternative Names: IMP-10

Latest Information Update: 10 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IMPACT Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

10 Mar 2025 Preclinical trials in Cancer in China (unspecified route), prior to March 2025 (IMPACT Therapeutics pipeline, March 2025)
28 May 2024 No recent reports of development identified for research development in Cancer in China
28 Apr 2020 IMP 10 is available for licensing as of 28 Apr 2020. www.impact therapeutics.com

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com